TAYSHA GENE THERAPIES INC (TSHA)
US8776191061 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.5M | 15.451M 518.04% | 8.423M -45.49% | 5.076M -39.74% | 4.845M -4.55% | 44.67M 821.98% | 135.78M 203.96% | 429.92M 216.63% | 796.81M 85.34% | 928.22M 16.49% | ||
| EBITDA YoY % growth | -172.78M -301.91% | -124.86M 27.73% | -70.003M 43.93% | -94.721M -35.31% | -97.257M -2.68% | 30.159M 131.01% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -173.27M -302.95% | -126.03M 27.26% | -71.374M 43.37% | -93.763M -31.37% | -97.615M -4.11% | -87.492M 10.37% | -84.092M 3.89% | -6.225M 92.60% | 219.15M 3,620.56% | 510.96M 133.16% | 638.31M 24.92% | |
| Operating Margin | N/A | -5,041.20% | -461.94% | -1,113.17% | -1,923.06% | -1,805.81% | -188.25% | -4.58% | 50.97% | 64.13% | 68.77% | |
| EPS YoY % growth | -4.63 -79.84% | -3.13 32.40% | 0.13 104.15% | -0.39 -396.23% | -0.39 -0.54% | -0.43 -10.12% | -0.51 -19.62% | -0.31 40.00% | 0.75 346.67% | 1.83 141.89% | 2.51 37.71% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 -109.20% | -0.09 7.07% | -0.10 -6.28% | -0.10 1.40% | -0.10 -15.06% |
| Revenue Q2Q % growth | 2.12M -41.18% | 1.74M -48.99% | 1.74M 56.47% | 1.776M -0.67% | 1.496M -29.43% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -22.458M -42.16% | -24.555M -0.93% | -25.163M -18.14% | -25.965M -23.29% | -26.217M -16.74% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.10 23.08% | -0.09 | -0.01 | -5.87% |
| Q2 2024 Q2Q % growth | -0.09 76.32% | -0.17 | 0.08 | 46.41% |
| Q1 2024 Q2Q % growth | -0.10 64.29% | -0.11 | 0.01 | 10.38% |
| Q4 2023 Q2Q % growth | 0.92 370.59% | -0.11 | 1.03 | 919.96% |
| Q3 2023 Q2Q % growth | -0.13 79.69% | -0.18 | 0.05 | 26.20% |
| Q2 2023 Q2Q % growth | -0.38 54.76% | -0.32 | -0.06 | -19.75% |
| Q1 2023 Q2Q % growth | -0.28 78.63% | -0.36 | 0.08 | 22.48% |
| Q4 2022 Q2Q % growth | -0.34 74.24% | -0.34 | 0.00 | -1.25% |
| Q3 2022 Q2Q % growth | -0.64 52.59% | -0.83 | 0.19 | 23.17% |
| Q2 2022 Q2Q % growth | -0.84 22.94% | -1.02 | 0.18 | 18.03% |
| Q1 2022 Q2Q % growth | -1.31 -50.57% | -1.09 | -0.22 | -20.35% |
| Q4 2021 Q2Q % growth | -1.32 -26.92% | -1.28 | -0.04 | -3.12% |
| Q3 2021 Q2Q % growth | -1.35 -5.47% | -1.10 | -0.25 | -22.74% |
| Q2 2021 Q2Q % growth | -1.09 | -0.86 | -0.23 | -27.27% |
| Q1 2021 Q2Q % growth | -0.87 | -0.57 | -0.30 | -51.55% |
| Q4 2020 Q2Q % growth | -1.04 | -0.38 | -0.66 | -171.90% |
| Q3 2020 Q2Q % growth | -1.28 | -0.18 | -1.10 | -617.09% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 1.788M -62.33% | 1.681M | 107K | 6.37% |
| Q2 2024 Q2Q % growth | 1.112M -53.57% | 2.717M | -1.605M | -59.07% |
| Q1 2024 Q2Q % growth | 3.411M -27.52% | 2.612M | 799K | 30.59% |
| Q4 2023 Q2Q % growth | 3.604M 44.16% | 2.703M | 901K | 33.33% |
| Q3 2023 Q2Q % growth | 4.746M | 2.141M | 2.605M | 121.67% |
| Q2 2023 Q2Q % growth | 2.395M | 1.9M | 495K | 26.05% |
| Q1 2023 Q2Q % growth | 4.706M | 1.02M | 3.686M | 361.37% |
| Q4 2022 Q2Q % growth | 2.5M | 8.345M | -5.845M | -70.04% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 18.91% | 0% | 2.09% |
| Revenue | 0% | -26.92% | 0% | -1.31% |